TRICAV-II Pivotal:TRIcvalve biCAVal 瓣膜系统,用于严重三尖瓣反流。 (TRICAV-II)
TricValve 经导管双腔瓣膜系统在严重三尖瓣反流 (TR) 受试者中的前瞻性、多中心、随机临床试验。
Pivotal trial to evaluate the safety and effectiveness of the P&F TricValve® Transcatheter Bicaval Valve System.
研究概览
地位
详细说明
The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TricValve System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with severe tricuspid regurgitation and unsuitable for approved transcatheter therapies. Subjects will be followed at discharge, 1 month, 30 days, 3 months, 6 months 12 months, and annually up to 5 years.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Thuy Olender
- 电话号码:+1 408-839-3809
- 邮箱:tolender@productsandfeatures.com
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- University of Alabama
-
-
Arizona
-
Phoenix、Arizona、美国、85013
- St. Joseph's Hospital and Medical Center
-
-
California
-
Sacramento、California、美国、95817
- UC Davis Health
-
San Diego、California、美国、92037
- Scripps Memorial Hospital La Jolla
-
San Francisco、California、美国、94143
- UCSF
-
San Jose、California、美国、94118
- Kaiser Permanente
-
首席研究员:
- Andrew Rassi, MD
-
接触:
- Cristina Casias
- 电话号码:510-318-4224
- 邮箱:cristina.casias@kp.org
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20010
- MedStar Washington Hospital Center (MWHC)
-
接触:
- Erin Collins
-
首席研究员:
- Toby Rogers, MD
-
-
Florida
-
Delray Beach、Florida、美国、33484
- Delray Medical Center
-
Largo、Florida、美国、33770
- HCA Florida Largo Hospital
-
首席研究员:
- Saurabh Sanon, MD
-
接触:
- Holly-Lynn Grospitch
- 电话号码:727-631-3721
- 邮箱:hollylynn-grospitch@hcahealthcare.com
-
Tampa、Florida、美国、33606
- Tampa General Hospital
-
-
Illinois
-
Glenview、Illinois、美国、60026
- Endeavor Health
-
-
Indiana
-
Indianapolis、Indiana、美国、46260
- Ascension Medical Group St. Vincent The Heart Center of Indiana
-
-
Kansas
-
Kansas City、Kansas、美国、66103
- University of Kansas Medical Center
-
-
Louisiana
-
Houma、Louisiana、美国、70360
- Cardiovascular Institute of the South
-
首席研究员:
- Peter Fail, MD
-
接触:
- Jenny Aucoin
- 电话号码:985-873-5037
- 邮箱:jennifer.aucoin@cardio.com
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Beth Israel Deaconess Medical Center
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital
-
Burlington、Massachusetts、美国、01805
- Lahey Hospital & Medical Center
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
Kansas City、Missouri、美国、64111
- Saint Luke's Mid America Heart Institute
-
St Louis、Missouri、美国、63110
- Washington University of St Louis
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- Hackensack University Medical Center
-
-
New York
-
Manhasset、New York、美国、11030
- Northwell Hospital
-
The Bronx、New York、美国、10467
- Montefiore Medical Center
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- Cleveland Clinic
-
首席研究员:
- Rishi Puri, MD
-
Columbus、Ohio、美国、43214
- Riverside Methodist Hospital
-
-
Oregon
-
Portland、Oregon、美国、97239
- Oregon Health
-
首席研究员:
- Firas Zahr, MD
-
接触:
- Halie Ropp
- 电话号码:503-494-1147
- 邮箱:ropph@ohsu.edu
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- MUSC
-
-
Texas
-
Houston、Texas、美国、77030
- Houston Methodist
-
Houston、Texas、美国、77030
- University of Texas (Memorial Hermann)
-
Plano、Texas、美国、75093
- Baylor Scott & White Medical
-
-
Utah
-
Murray、Utah、美国、84107
- Intermountain Heart Institute - Intermountain Medical Center
-
首席研究员:
- Brian Whisenant, MD
-
接触:
- McKenna Jensen
- 电话号码:801-917-0978
- 邮箱:mcKenna.jensen@imail.org
-
-
Virginia
-
Charlottesville、Virginia、美国、22903
- UVA School of Medicine
-
Norfolk、Virginia、美国、23507
- Sentara Healthcare
-
Roanoke、Virginia、美国、24014
- Carilion Clinic
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Eligibility Criteria for Randomized Cohort:
Inclusion Criteria:
- Age between 18 years and 85 years old, at the time of signing the informed consent.
- Severe tricuspid regurgitation (TR) and Caval Reflux (CR), as determined by the qualifying transthoracic echocardiogram (TTE) confirmed by an echocardiography Core Lab. TVARC criteria will be used for the definition of TR severity.
- NYHA Class II-III-IVa (not on inotropes, IABP or LVAD) or heart failure (HF) admission in the past 6 months.
- Adequately treated with optimal medical therapy (OMT) for heart failure per the local Heart Team at the time of TR assessment for eligibility (TTE). OMT includes stable oral diuretic medications.
- High risk for open surgery and is appropriate for transcatheter tricuspid therapies according to the local heart team.
- Patient is unsuitable for approved transcatheter therapies and is eligible for the TricValve procedure, based on review of screening/baseline data and imaging core lab measurements by Central Screening Committee.
- For females of childbearing potential, negative pregnancy test.
- Capable and willing to provide signed informed consent
Exclusion Criteria:
CONCOMITANT PROCEDURES
-
Patient had a recent MI, stroke, or cardiovascular accident; underwent coronary artery bypass graft surgery, had a percutaneous coronary intervention or other major cardiovascular surgery within 90 days prior to TricValve implantation.
-
Patient requires another planned major cardiac procedure, including left-sided transcatheter intervention or surgery (e.g. severe aortic stenosis, severe mitral regurgitation), coronary artery bypass or PCI or pulmonary valve correction.
CARDIOVASCULAR CONDITIONS
-
LVEF ≤ 30% on echocardiography.
-
Evidence of intracardiac, inferior vena cava (IVC), or femoral venous mass, thrombus or vegetation.
-
Severe right ventricular dysfunction.
-
Cardiac amyloidosis.
-
Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or right heart catheterization.
-
Lower extremity venous thrombosis and/or the presence of an IVC filter at the time of or 6 months prior to the TricValve procedure.
-
Hemodynamically significant pericardial effusion.
-
Hemodynamic instability, cardiogenic shock, inotropic support, intra-aortic balloon pump or acute heart failure within 30 days prior to the TricValve procedure.
-
Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, transplantation) (ACC/ AHA/ ESC/ EACTS Stage D heart failure).
-
Presence of significant congenital or acquired heart disease such as RV dysplasia, arrhythmogenic RV or other conditions that could interfere with the TricValve procedure.
ALLERGIES / INTOLERANCE
-
Any known allergy or hypersensitivity to nitinol, bovine tissue, or contrast media that cannot be adequately treated with pre-medication.
-
Unable to tolerate anticoagulation/antiplatelet therapy
COMORBIDITIES
-
Any known life-threatening condition with an estimated life span of less than 12 months.
-
Platelet count < 75,000/mm3
-
Child-Pugh Severity Class C (10-15 points).
-
Severe renal insufficiency with estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 or requiring chronic renal replacement therapy at the time of enrollment.
-
Endocarditis or active/ongoing infection requiring antibiotics.
-
Unable to walk at least 100 meters in a 6-minute walk test.
-
Known bleeding or clotting disorders or patient refuses blood transfusion.
-
Active gastrointestinal (GI) bleeding within 3 months of TricValve procedure.
-
Prior Malignancy: this study excludes participants at material risk of near-term cancer-related morbidity/mortality that could confound 12-month outcomes. This study allows the inclusion of fully treated, remote malignancies with documented No Evidence of Disease (NED)" criteria
a. History of any malignancy within 5 years prior to randomization or any active malignancy, except: i. Adequately treated non-melanoma skin cancer (basal or squamous cell) with no evidence of disease, or ii. Carcinoma in situ (e.g., cervical, breast DCIS) treated with curative intent and no evidence of disease.
b. Participants with a prior malignancy diagnosed >5 years before randomization are eligible if they meet all of the "No Evidence of Disease (NED)" criteria as specified below: i. No signs/symptoms of cancer on history and physical exam per standard of care; ii. No radiologic evidence of disease on surveillance imaging if such imaging is routinely indicated for that tumor type (not protocol-mandated); iii. Tumor markers (if applicable for that cancer) not suggestive of recurrence (e.g., stable/undetectable within site's lab reference and oncologist's judgment); iv. No active anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, targeted therapy, radiotherapy) and none planned; v. Treating oncologist's attestation (or primary physician if oncology follow-up is complete) that the participant is disease-free and appropriate for participation.
GENERAL EXCLUSIONS
-
Use or participation in other investigational device or drug study in which the patient has not reached a primary endpoint to treat cardiovascular conditions related to the outcomes of the current study.
-
Any other condition that would preclude the ability to meet study requirements in the opinion of the investigator.
-
Psychiatric/behavioral issues or other medical or social conditions that preclude valid consent and follow-up
-
Pregnant or breastfeeding subjects and those who plan pregnancy during the clinical investigation follow-up period.
Eligibility Criteria for Single Arm Cohort:
Inclusion Criteria:
- Age > 85 years.
- NYHA Class III-IV, on intravenous inotropes, IABP or LVAD.
- LVEF ≤ 30% on echocardiography.
- Severe RV dysfunction.
- Severe pulmonary hypertension (PH), defined as Pulmonary artery systolic pressure (PASP) >65 mmHg assessed with Echo Doppler and /or mean Pulmonary Artery Pressure (mPAP >35) by right heart catheterization.
- Renal insufficiency: eGFR between 25 and 30 mL/min/ 1.73 m² or on chronic renal replacement therapy.
- Patient unable to walk a minimum distance of 100 mt during 6 minute walk test.
- Prior malignancy not meeting the requirements applied for the Randomized Cohort, specified in Exclusion Criterion #23.
- Comorbidities precluding inclusion in the Randomized Cohort (exclusion criteria #15 to #24).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:TricValve System + Optimal medical therapy (OMT)
Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy (OMT) in patients with caval reflux and tricuspid regurgitation. |
• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy
其他名称:
Optimal medical therapy
其他名称:
|
|
有源比较器:Optimal medical therapy (OMT) Alone
OMT alone in patients with caval reflux and tricuspid regurgitation |
Optimal medical therapy
其他名称:
|
|
实验性的:TricValve Single Arm Registry
Single-Arm Registry for Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with OMT in patients with caval reflux and tricuspid regurgitation who are not eligible for randomization |
• Heterotopic Transcatheter Valve Replacement (TVR) with the TricValve System in conjunction with optimal medical therapy
其他名称:
Optimal medical therapy
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Randomized Cohort: Caval Reflux (CR) grade reduction
大体时间:6 months
|
Reduction in Caval Reflux (CR) assessed by the echocardiography core laboratory. The CR will be assessed using the 3-grade scale: Grade 1 (no reflux, reflux extending for less than 1 cm below the diaphragm), Grade 2 ( reflux extending for less than 3 cm), Grade 3 (reflux of 3 cm or more). Lower grades of CR are better. |
6 months
|
|
Randomized Cohort: Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement
大体时间:6 months
|
Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm. |
6 months
|
|
Randomized Cohort: Rate of Major Adverse Events (MAE)
大体时间:30 days
|
Rate of Major Adverse Events (MAE) in experimental arm (TricValve + OMT) |
30 days
|
|
Randomized Cohort: Hierarchical composite endpoint: all-cause mortality, RVAD implantation or heart transplant, tricuspid valve surgery or percutaneous tricuspid intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improv
大体时间:1 year
|
Comparison of clinical outcomes using a single hierarchical analysis. Treatment effect will be summarized using Win Ratio statistics, where a value greater than 1 indicates improved outcomes in the experimental group compared with the comparator arm. |
1 year
|
|
Registry Cohort: Rate of Major Adverse Events (MAE)
大体时间:30 days
|
Rate of Major Adverse Events (MAE) in single arm registry |
30 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Randomized Cohort: Percentage of Device- and/or Procedure-related MAEs
大体时间:1 year
|
Rate of Major Adverse Events |
1 year
|
|
Randomized Cohort: All-Cause mortality and Cardiovascular Mortality
大体时间:6 months and 1 year
|
Number of deaths from any cause as well as cardiovascular events |
6 months and 1 year
|
|
Randomized Cohort: Heart Failure Hospitalizations (HFH)
大体时间:6 months and 1 year
|
Number of Heart Failure Hospitalizations and worsening HF events without hospitilization |
6 months and 1 year
|
|
Randomized Cohort: RVAD Implantation or Heart Transplant
大体时间:6 months and 1 year
|
Number of patients requiring RVAD Implantation or Heart Transplant |
6 months and 1 year
|
|
Randomized Cohort: Atrial Fibrillation
大体时间:1 year
|
New onset of atrial fibrillation |
1 year
|
|
Randomized Cohort: Quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) .
大体时间:6 months and 1 year
|
Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL) |
6 months and 1 year
|
|
Randomized Cohort: Changes in symptom status New York Heart Association (NYHA class)
大体时间:6 months and 1 year
|
Reduction of at least 1 class from baseline. The NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest). |
6 months and 1 year
|
|
Randomized Cohort: Changes in functional capacity (6-minute walk test, 6MWT).
大体时间:6 months and 1 year
|
Improvement of 6-minute walk distance of at least 30 meters from baseline. |
6 months and 1 year
|
|
Registry Cohort: Heart Failure Hospitalization
大体时间:1 year
|
Comparison of the 12-month post-procedure HFH rate with the 12-month pre-procedure rate |
1 year
|
|
Registry Cohort: Changes in Quality of life (by Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score).
大体时间:1 year
|
Change from baseline to 12 months. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life (QOL) |
1 year
|
|
Roll-In Cohort: Percentage of Device- and/or Procedure-related MAEs
大体时间:1 year
|
Rate of Major Adverse Events |
1 year
|
|
Roll-In Cohort: All-Cause mortality and Cardiovascular Mortality
大体时间:6 months and 1 year
|
Number of deaths from any cause as well as cardiovascular events |
6 months and 1 year
|
|
Roll-In Cohort: Heart Failure Hospitalizations (HFH)
大体时间:6 months and 1 year
|
Number of Heart Failure Hospitalizations and worsening HF events without hospitalization |
6 months and 1 year
|
|
Roll-In Cohort: RVAD Implantation or Heart Transplant
大体时间:6 months and 1 year
|
Number of patients requiring RVAD Implantation or Heart Transplant |
6 months and 1 year
|
|
Roll-In Cohort: Atrial Fibrillation
大体时间:1 year
|
New onset of atrial fibrillation |
1 year
|
|
Roll-In Cohort: Quality of life as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ).
大体时间:6 months and 1 year
|
Improvement of at least 10 points from baseline. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better Quality of Life |
6 months and 1 year
|
|
Roll-In Cohort: New York Heart Association (NYHA) functional class
大体时间:6 months and 1 year
|
Reduction of at least 1 class from baseline. NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest). |
6 months and 1 year
|
|
Roll-In Cohort: 6-minute walk test (6MWT).
大体时间:6 months and 1 year
|
Improvement of 6-minute walk distance of at least 30 meters from baseline. |
6 months and 1 year
|
合作者和调查者
出版物和有用的链接
一般刊物
- Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A, Cruz-Gonzalez I, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Blasco-Turrion S, Sanchez-Luna JP, Revilla-Orodoea A, Redondo A, Zamorano JL, Puri R, Iniguez-Romo A, San Roman A. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention. 2023 Aug 7;19(5):e450-e452. doi: 10.4244/EIJ-D-23-00077. No abstract available.
- Blasco-Turrion S, Briedis K, Estevez-Loureiro R, Sanchez-Recalde A, Cruz-Gonzalez I, Pascual I, Mascherbauer J, Abdul-Jawad Altisent O, Nombela-Franco L, Pan M, Trillo R, Moreno R, Delle Karth G, Sanchez-Luna JP, Gonzalez-Gutierrez JC, Revilla-Orodoea A, Zamorano JL, Gomez-Salvador I, Puri R, San Roman JA, Amat-Santos IJ. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes. JACC Cardiovasc Interv. 2024 Jan 8;17(1):60-72. doi: 10.1016/j.jcin.2023.10.043. Epub 2023 Dec 6.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.